NRD
BMRN icon

Nebula Research & Development’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nebula Research & Development’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,071
Closed -$1.98M – 126
2025
Q2 		$1.98M Buy
36,071
+18,171
+102% +$1.07M 0.17% 193
2025
Q1 		$1.27M Sell
17,900
-25,285
-59% -$1.7M 0.12% 288
2024
Q4 		$2.84M Sell
43,185
-9,514
-18% -$637K 0.33% 54
2024
Q3 		$3.7M Buy
+52,699
New +$4.41M 0.44% 14
2024
Q2 		– Sell
-5,114
Closed -$447K – 813
2024
Q1 		$447K Buy
+5,114
New +$458K 0.1% 397

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nebula Research & Development's BMRN Position: Q3 2025 in Review

Nebula Research & Development sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 36,071 shares — an estimated $1.98M sold.

Nebula Research & Development first reported a position in BMRN in Q1 2024 and held it in 5 quarters. The position peaked at $3.7M in Q3 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Nebula Research & Development reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 36,071 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $1.98M.
  • Nebula Research & Development first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Nebula Research & Development's BioMarin Pharmaceuticals position peaked at $3.7M in Q3 2024.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.